Andreia R. Valente

Lisbon, 1749016, Portugal

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Lysosome-targeted Ru(II)-cyclopentadienyl organometallic anticancer complexes.

Lysosome-targeted Ru(II)-cyclopentadienyl organometallic anticancer complexes.

Journal: Dalton transactions (Cambridge, England : 2003)

Published: November 06, 2025

A novel combinatory treatment against a CDDP-resistant non-small cell lung cancer based on a Ruthenium(II)-cyclopentadienyl compound.

A novel combinatory treatment against a CDDP-resistant non-small cell lung cancer based on a Ruthenium(II)-cyclopentadienyl compound.

Journal: Pharmacological research

Published: April 01, 2024

Schiff bases and their metal complexes to target and overcome (multidrug) resistance in cancer.

Schiff bases and their metal complexes to target and overcome (multidrug) resistance in cancer.

Journal: European journal of medicinal chemistry

Published: February 27, 2024

Paraptotic Cell Death as an Unprecedented Mode of Action Observed for New Bipyridine-Silver(I) Compounds Bearing Phosphane Coligands.

Paraptotic Cell Death as an Unprecedented Mode of Action Observed for New Bipyridine-Silver(I) Compounds Bearing Phosphane Coligands.

Journal: Journal of medicinal chemistry

Published: February 24, 2024

Novel family of [RuCp(N,N)(P)]+ compounds with simultaneous anticancer and antibacterial activity: Biological evaluation and solution chemistry studies.

Novel family of [RuCp(N,N)(P)]+ compounds with simultaneous anticancer and antibacterial activity: Biological evaluation and solution chemistry studies.

Journal: European journal of medicinal chemistry

Published: September 29, 2023

Lead to hit ruthenium-cyclopentadienyl anticancer compounds: Cytotoxicity against breast cancer cells, metabolic stability and metabolite profiling.

Lead to hit ruthenium-cyclopentadienyl anticancer compounds: Cytotoxicity against breast cancer cells, metabolic stability and metabolite profiling.

Journal: Journal of inorganic biochemistry

Published: September 19, 2023

Fighting Multidrug Resistance with Ruthenium-Cyclopentadienyl Compounds: Unveiling the Mechanism of P-gp Inhibition.

Fighting Multidrug Resistance with Ruthenium-Cyclopentadienyl Compounds: Unveiling the Mechanism of P-gp Inhibition.

Journal: Journal of medicinal chemistry

Published: August 24, 2023

Iron(II)-cyclopentadienyl compounds are cytotoxic against colon adenocarcinoma cell lines: Ethylenebis(diphenylphosphane) vs. triphenylphosphane.

Iron(II)-cyclopentadienyl compounds are cytotoxic against colon adenocarcinoma cell lines: Ethylenebis(diphenylphosphane) vs. triphenylphosphane.

Journal: Journal of inorganic biochemistry

Published: August 10, 2023

Evaluation of the Antiproliferative Properties of CpRu Complexes Containing N-Methylated Triazaphosphaadamantane Derivatives.

Evaluation of the Antiproliferative Properties of CpRu Complexes Containing N-Methylated Triazaphosphaadamantane Derivatives.

Journal: Bioinorganic chemistry and applications

Published: June 05, 2023

New Ruthenium-Cyclopentadienyl Complexes Affect Colorectal Cancer Hallmarks Showing High Therapeutic Potential.

New Ruthenium-Cyclopentadienyl Complexes Affect Colorectal Cancer Hallmarks Showing High Therapeutic Potential.

Journal: Pharmaceutics

Published: May 13, 2023

First iron(II) organometallic compound acting as ABCB1 inhibitor.

First iron(II) organometallic compound acting as ABCB1 inhibitor.

Journal: European journal of medicinal chemistry

Published: March 21, 2023

Ruthenium(II)-Cyclopentadienyl-Derived Complexes as New Emerging Anti-Colorectal Cancer Drugs.

Ruthenium(II)-Cyclopentadienyl-Derived Complexes as New Emerging Anti-Colorectal Cancer Drugs.

Journal: Pharmaceutics

Published: May 18, 2022

Showing 1-12 of 33

Last Updated: 09/26/2026